- 1 Title: Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States 2 Veterans Aged 54-75 Years
 - Authors: Christopher T. Rentsch, Ph.D.^{1,2}, Farah Kidwai-Khan, MS^{1,3*}, Janet P. Tate, Sc.D.^{1,3*},
- Lesley S. Park, Ph.D.^{4*}, Joseph T. King, Jr., M.D.^{1,5*}, Melissa Skanderson, MSW^{1*}, Ronald G. 5
- Hauser, M.D.^{1,6}, Anna Schultze, Ph.D.², Christopher I. Jarvis, Ph.D.², Mark Holodniy, M.D.^{7,8}, 6
- Vincent Lo Re III, M.D.⁹, Kathleen M. Akgün, M.D.^{1,3}, Kristina Crothers, M.D.¹⁰, Tamar H. Taddei, 7 M.D. 1,3, Matthew S. Freiberg, M.D. 11,12, and Amy C. Justice, M.D. 1,3,13 8
- 1. VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT, 10 11 US, 06516
 - 2. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK, WC1E 7HT
 - 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, US, 06520
 - 4. Stanford Center for Population Health Sciences, Stanford University School of Medicine, Stanford, CA, US, 94305
 - 5. Department of Neurosurgery, Yale School of Medicine, New Haven, CT, US, 06520
 - 6. Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, US, 06520
 - 7. VA Palo Alto Healthcare System, US Department of Veterans Affairs, Palo Alto, CA, US,
 - 8. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, US, 94305
 - 9. Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US, 19104
 - 10. VA Puget Sound Health Care System and Department of Medicine, University of Washington School of Medicine, Seattle, WA, US, 98104
 - 11. Geriatric Research Education and Clinical Center (GRECC), US Department of Veterans Affairs, Tennessee Valley Health Care System, Nashville, TN, US 37212
 - 12. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, US, 37232
 - 13. Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, US, 06511
 - *These authors contributed equally
 - Sources of support: This work was supported by National Institute on Alcohol Abuse and Alcoholism [U01-AA026224, U24-AA020794, U01-AA020790, U10-AA013566].
- 41 **Conflicts of interest:** The authors declare no conflicts of interest.
- 43 Words: 2739

4

9

12

13

14

15

16

17

18 19

20

21 22

23

24

25

26 27

28

29

30

31

32

33 34

35 36

37 38

39

40

42

44 Tables/Figures: 4/1

Question: What are the demographic and clinical characteristics associated with testing positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization and intensive care among Veterans in the United States?

Findings: In this retrospective cohort study of 2,026,227 Veterans aged 54-75 years and active in care, 585/3,789 (15.4%) tested Covid-19+. Black race was strongly associated with Covid-19+, but not with hospitalization or intensive care. Among Covid-19+, laboratory abnormalities and a summary measure of physiologic injury were strongly associated with hospitalization and intensive care.

Meaning: Racial differences in testing positive for Covid-19 may be an underestimate of the general population as racial health disparities in the Veterans Affairs Healthcare System tend to be smaller than in the private sector. Risk of hospitalization and intensive care may be better characterized by laboratory measures and vital signs than by comorbid conditions or prior medication exposure.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Abstract Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (Covid-19), an evolving pandemic. Limited data are available characterizing SARS-Cov-2 infection in the United States. Objective: To determine associations between demographic and clinical factors and testing positive for coronavirus 2019 (Covid-19+), and among Covid-19+ subsequent hospitalization and intensive care. Design, Setting, and Participants: Retrospective cohort study including all patients tested for Covid-19 between February 8 and March 30, 2020, inclusive. We extracted electronic health record data from the national Veterans Affairs Healthcare System, the largest integrated healthcare system in the United States, on 2,026,227 patients born between 1945 and 1965 and active in care. Exposures: Demographic data, comorbidities, medication history, substance use, vital signs, and laboratory measures. Laboratory tests were analyzed first individually and then grouped into a validated summary measure of physiologic injury (VACS Index). Main Outcomes and Measures: We evaluated which factors were associated with Covid-19+ among all who tested. Among Covid-19+ we identified factors associated with hospitalization or intensive care. We identified independent associations using multivariable and conditional multivariable logistic regression with multiple imputation of missing values. Results: Among Veterans aged 54-75 years, 585/3,789 (15.4%) tested Covid-19+. In adjusted analysis (C-statistic=0.806) black race was associated with Covid-19+ (OR 4.68, 95% CI 3.79-5.78) and the association remained in analyses conditional on site (OR 2.56, 95% CI 1.89-3.46).

In adjusted models, laboratory abnormalities (especially fibrosis-4 score [FIB-4] >3.25 OR 8.73, 95% CI 4.11-18.56), and VACS Index (per 5-point increase OR 1.62, 95% CI 1.43-1.84) were strongly associated with hospitalization. Associations were similar for intensive care. Although significant in unadjusted analyses, associations with comorbid conditions and medications were substantially reduced and, in most cases, no longer significant after adjustment.

Conclusions and Relevance: Black race was strongly associated with Covid-19+, but not with hospitalization or intensive care. Among Covid-19+, risk of hospitalization and intensive care may be better characterized by laboratory measures and vital signs than by comorbid conditions or prior medication exposure.

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes coronavirus disease 2019 (Covid-19) and is an evolving pandemic. Limited data are available characterizing SARS-Cov-2 infection in the United States. Unadjusted analyses restricted to Covid-19 cases in China, 1-5 Italy, 6 and the United States 7,8 suggest that older age, diabetes, chronic obstructive lung disease (COPD), hypertension, vascular disease, renal disease, and liver disease are associated with more severe disease. Further, while some have speculated that use of angiotensin converting enzyme inhibitor (ACE), angiotensin || receptor blockers (ARB), and nonsteroidal anti-inflammatory drugs (NSAID) may exacerbate disease. 9,10 no analysis of this question has been published. The Department of Veterans Affairs (VA) is the largest integrated healthcare system in the United States. All care is recorded in a national electronic health record with daily uploads into a central data repository. As a result, it is possible to extract data on patients tested for Covid-19, including outpatient and inpatient records, laboratory values, and pharmacy fill/refill data. When a well-characterized longitudinal cohort is supplemented with Covid-19 testing data, it is possible to answer important questions rapidly using validated methods. The VA Birth Cohort includes all Veterans born between 1945 and 1965, over 2 million living individuals aged 54-75 years, ^{11,12} a demographic at particularly high risk of adverse outcomes from Covid-19.¹⁻⁴ Using unadjusted and adjusted analyses, we consider a wide range of factors

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

either associated with testing positive for Covid-19 and subsequent hospitalization and intensive care in the national VA system as of March 30, 2020. Methods Data Source Using data from the VA national Corporate Data Warehouse on members of the VA Birth Cohort, we identified patients tested for Covid-19 from date of first recorded VA test on February 8, 2020 through March 30, 2020. Available data included demographics, outpatient and inpatient encounters, diagnoses, laboratory results, vital signs, health factors (e.g., smoking and alcohol health behaviors), and pharmacy dispensing records. VA Birth Cohort was approved by the Institutional Review Boards of VA Connecticut Healthcare System and Yale University. It has been granted a waiver of informed consent and is Health Insurance Portability and Accountability Act compliant. Data Collection We selected previously validated cohort characteristics and those that have been evaluated in prior Covid-19 reports. 1,13 Baseline was defined as the date of specimen collection for the Covid-19 test unless testing occurred during hospitalization, in which case it was date of admission. Demographics included age at baseline, sex, race/ethnicity, and rural/urban residence. Residence was defined using geographic information system coding based upon established criteria.14

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Main Study Outcomes We examined three outcomes: 1) testing positive for SARS-CoV-2 (Covid-19+), 2) hospitalization, and 3) admission to an intensive care unit (ICU). We used VA inpatient bed section codes 12 (medical) and 13 (cardiac) to identify ICU admission. Covid-19 tests We identified Covid-19 tests conducted in the VA using text searching of laboratory results containing terms consistent with SARS-CoV-2 or Covid-19. If a patient had more than one test and all were negative we selected first negative, otherwise we used date of first positive. Patients for whom results were pending (n=93) or inconclusive (n=33) were excluded. Nearly all tests utilized nasopharyngeal swabs, 1% were from other sources. Testing was performed in VA, state public health and commercial reference laboratories using emergency use authorization approved SARS-CoV-2 assays. Comorbidity We extracted diagnostic codes for asthma, cancer, COPD, chronic kidney disease, diabetes mellitus, hypertension, liver disease, vascular disease, and alcohol use disorder (definitions provided in eTable 1). We used a validated algorithm to capture smoking status derived from health factors.15 Pharmacy Data

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

We collected pharmacy fills for ACE/ARBs, chemotherapy and immunosuppressive drugs, and prescription NSAIDs and determined which medications were active in the year prior to testing. Exposure windows for NSAIDS ended 14 days prior to baseline to minimize the potential of protopathic bias. Exposure windows for other medications not used to treat Covid-19 symptoms ended three days prior to baseline. Vital Signs, Clinical Laboratory Data, and a Summary Measure of Physiologic Injury Vital signs measured within two days of baseline included body mass index (BMI), oxygen saturation, pulse, systolic blood pressure, and temperature. We chose laboratory findings closest to baseline within a year prior or up to one week after baseline. Measures included alanine aminotransferase, albumin, aspartate aminotransferase, creatinine, estimated glomerular filtration rate, ¹⁶ fibrosis-4 score (FIB-4), ¹⁷ hemoglobin, platelet count, total white blood cell count, and lymphocyte count. We calculated a validated composite measure of physiologic injury (VACS Index) which includes age, BMI, and all previously mentioned laboratory measures save lymphocyte count (details in eMethods). Statistical Analysis We evaluated characteristics of patients undergoing Covid-19 testing, and among Covid-19+, factors associated with hospital admission and intensive care, using chi-square, Fisher's exact, and Wilcoxon rank-sum tests, as appropriate. For bivariate comparisons, statistical significance reflects complete case analysis. When modeling Covid-19+, we restricted analyses to factors available when initially evaluating a patient (i.e., demographic data, comorbid conditions,

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

medication history, health behaviors, and vital signs). Because age, black race, ACE/ARB use, and NSAID use are of special interest, we included them in all multivariable models. Otherwise, variables significant at p<0.05 in unadjusted analyses were included in the multivariable models. When modeling hospital admission and intensive care, we compared C-statistics for models including individual laboratory values to a model including VACS Index. In post hoc analyses we explored the association between black race and Covid-19+ with a multivariable model conditioned on site, among sites having at least five positive tests. We report missing data for each variable. We used multiple imputation to impute missing laboratory measures, vital signs, and smoking status. The imputation model included outcomes and all covariates. Estimates from regressions performed on 10 imputed data sets were combined using Rubin's rules.²⁰ Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata version 14.2 (StataCorp, LLC., College Station, TX). We used R version 3.6.3 to map Covid-19 cases in the VA system overall and those captured in the VA Birth Cohort. Results In the year prior to the Covid-19 outbreak, the VA Birth Cohort included 2,026,277 living individuals: 1,866,256 (92.1%) men and 159,971 (7.9%) women. The cohort includes 1,369,454 (67.6%) white, 402,295 (19.9%) black, 106,639 (5.3%) Latinx, and 147,839 (7.3%) other or unknown race/ethnicity. More than a third of the subjects (745,284 or 36.8%) were 70-75 years of age, 23.3% (n=472,732) were 65-69 years old, 20.1% (n=407,900) were 60-64 years old, and

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

19.8% (n=400,311) were 54-59 years old. Of these, 3,789 individuals have been tested for Covid-19 (18.7 per 10,000 persons) since February 8, 2020 through March 30, 2020. Testing per 10,000 persons varied by race, sex, age, and residence (p<0.001 for all). Black Veterans were more likely to be tested than white Veterans (28.0 versus 15.6). Women were more likely to be tested than men (23.3 versus 18.3). Testing generally decreased with age (age 54-59: 21.5; age 60-64: 22.2; age 65-69: 18.6; and age 70-75: 15.4). Veterans living in urban settings were more likely to be tested than those in rural settings (39.2 vs. 5.8). Among those tested, median age was 65.7 years (**Table 1**), 90.2% were male, 29.7% were black, and 81.1% lived in urban settings. Common comorbid conditions were hypertension (65.0%), diabetes mellitus (37.8%), vascular disease (28.9%), COPD (26.2%), and alcohol use disorder (13.9%). Receipt of ACE/ARBs (40.5%) or NSAIDs (30.5%) was common. Among those tested, 42.3% were current smokers, 40.8% were obese (BMI >30 kg/m²), 7.7% were febrile (\geq 100.4°F), 13.1% were hypoxic (oxygen saturation \leq 93%), and 35.4% were tachycardic (pulse \geq 90 beats per minute). Testing Positive vs. Negative for Covid-19 Of the 3,789 patients tested in the VA Birth Cohort, 585 (15.4%, 95% CI 14.3-16.6) were Covid-19+, representing approximately half (585/1244, 47%) of all Covid-19+ patients in the VA as of March 30, 2020 (Figure 1a and eFigure 1). In unadjusted analyses, factors associated with Covid-19+ (Table 1) included male sex, black race, urban residence, chronic kidney disease,

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

diabetes, and hypertension (all p<0.003). Smoking, COPD, and alcohol use disorder were associated with a lower probability of a positive test (all p<0.001). No medication exposure was associated with a positive test. Vital signs associated with Covid-19+ included higher BMI, tachycardia, and higher temperature (all p<0.001). All laboratory values were associated with Covid-19+ (all p<0.001). Composite variables, eGFR and FIB-4, were also strongly associated (both p < 0.001). In multivariable analyses (Table 2, C-statistic=0.806), black race (OR 4.68,8 95% CI 3.79-5.78), male sex (OR 3.17, 95% CI 2.03-4.94), urban residence (OR 1.60, 95% CI 1.17-2.20), higher temperature (OR 1.70, 95% CI 1.58-1.84 per 1°F), lower systolic blood pressure (OR 1.44, 95% CI 1.16-1.78), and prior use of NSAIDS (OR 1.27, 95% CI 1.02-1.58) were associated with increased likelihood of Covid-19+. Current smoking (OR 0.45, 95% CI 0.35-0.57), alcohol use disorder (OR 0.58, 95% CI 0.41- 0.83), and COPD (OR 0.67, 95%CI 0.50-0.88) were associated with decreased likelihood of Covid-19+. Results were similar in complete case analysis (eTable 2). In post hoc analyses, we observed that black Veterans were more likely to be tested at sites with higher Covid-19 prevalence (Figure 1b). A model conditional on site (Table 2) reduced the association with black race (OR 2.56, 95% CI 1.89-3.46) and increased the association with male sex (OR 3.85, 95% CI 2.20-6.74). Associations with other factors were consistent with unconditional estimates. Risk Factors for Hospitalization and Intensive Care

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

Among 585 Covid-19+ patients, 297 (50.8%, 95% CI 46.6-54.9%) were hospitalized and 122 (20.9%, 95% Cl 17.6-24.4%) received intensive care. In bivariate analyses, age, chronic kidney disease, COPD, diabetes, hypertension, vascular disease, ACE/ARB exposure, and decreased oxygen saturation, and elevated temperature were associated with hospitalization and intensive care (all p<0.05, Table 3a and Table 3b). All laboratory abnormalities investigated were associated with hospitalization and intensive care (all p<0.05). Median VACS Index scores varied substantially between those hospitalized versus not hospitalized (78.7 vs. 66.2, p<0.001) and between those receiving and not receiving intensive care (82.0 vs. 69.4, p<0.001). Parallel models, first adjusted for all significant factors identified in bivariate analyses and then substituting VACS Index for all laboratory tests, demonstrated good discrimination for hospitalization (Table 4, C-statistics: 0.859, 0.834) and intensive care (C-statistics: 0.876, 0.835). White blood cell count, lymphocyte count, eGFR, albumin and FIB-4 were all independently associated with hospitalization and intensive care (Table 4). The most pronounced association was for patients with FIB-4>3.25 - adjusted OR 8.73 (95% CI 4.11-18.56) for hospitalization and 8.40 (95% CI 2.90-24.28) for intensive care – compared to those with FIB-4<1.45. Of note, associations were stronger for FIB-4 and eGFR than for components of these measures (data not otherwise shown). While COPD, diabetes, hypertension, kidney disease, vascular disease and exposure to ACE/ARB exposure were associated with hospitalization and intensive care in unadjusted analyses, they

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

were not significantly associated after adjusting for laboratory abnormalities and vital signs (Table 4). Results were similar in complete case analysis (eTable 3). Discussion Our analysis represents over 2 million veterans, aged 54-75 years, receiving care in the largest integrated healthcare system in the United States. The study was conducted within an established cohort and based on well annotated national electronic health record data, enabling a rapid and reliable analysis of Covid-19 testing and initial outcomes. As a result, we were able to validate and extend previous findings, to include a careful consideration of who is Covid-19+ and, given a positive test, what factors were independently associated with hospitalization and intensive care. We found that black Veterans were twice as likely to be tested and 2.5 times as likely to test positive than non-black Veterans, even after adjusting for urban residence and conditioning on geographic location. While we saw modest evidence of an association between exposure to NSAIDs and risk of Covid-19+, vital signs and laboratory measures better characterized risk of hospitalization and intensive care than did comorbid diagnoses or prior medication exposures. In unadjusted analyses, black Veterans were over four times as likely to test positive compared to non-black Veterans; adjusting for urban versus rural residence did not change this association. While black Veterans were much more likely to be tested at high prevalence facilities, conditioning our analysis by site did not eliminate the association; black race retained over a two-fold increased risk for testing Covid-19+. Of note, black Veterans were also more

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

likely to be tested, which could dilute the proportion positive. Further, black Veterans did not experience higher rates of hospitalization or intensive care. Based on prior experience with 1918 Spanish Flu and 2009 H1N1 epidemic, public health experts have warned that minority populations may be at higher risk of infection due to reduced capacity to implement physical distancing. 21,22 Our findings may be an underestimate of the US population as racial health disparities in VA tend to be smaller than in the private sector.²³ Women were more likely to be tested for Covid-19 than men, and men were twice as likely to test positive. This association strengthened after adjustment and in conditional analyses (Table 2) but should be considered preliminary given limited numbers of women in this analysis. As reported previously²⁴ elevated temperature was independently associated with testing positive, hospital admission and intensive care, underscoring the value of including fever in the current testing algorithms. Findings from the multivariable regression suggest that other factors might also be used to indicate a test, including black race, male sex, and lack of an alternative explanation for cough symptoms. To wit, we found that current smoking, COPD, and alcohol use disorder, factors that generally increase risk of pneumonia, were associated with decreased probability of testing positive. While they were not associated with hospitalization or intensive care, it is too early to tell if these factors are associated with subsequent outcomes such as respiratory failure or mortality.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

Presence of particular comorbid diagnoses may be less prognostic than overall acute on chronic injury reflected in laboratory abnormalities largely encompassed in the VACS Index. In unadjusted analyses, several comorbid conditions were associated with hospitalization and intensive care but were not independently associated after adjusting for vital signs and laboratory data. Further, while elevated white blood cell counts and decreased lymphocyte counts were associated with hospitalization and intensive care, the pronounced independent association with FIB-4 (a composite of platelets and transaminases) and albumin suggest that virally induced hepatic inflammation may be a harbinger of the cytokine storm. 25-27 VACS Index, which includes FIB-4, albumin, and white blood cell count, is predictive of mortality in many clinical settings. 18 A five-point difference in score corresponds to a 30% difference in mortality. The 12.5-point difference in medians between the Veterans who were and were not admitted, and the 12.6-point difference between those who received and did not receive intensive care underscores the wide range of prognoses seen with Covid-19. Future work will need to determine whether VACS Index might be used in medical triage of Covid-19+ patients. Our analysis is one of the first to address concerns regarding exposure to NSAIDS and ACE/ARBs and Covid-19. 9,10 We found NSAID exposure was modestly associated with Covid-19+ in unadjusted and adjusted analyses, but not with hospitalization or intensive care. Among those testing positive, ACE/ARB exposure was associated with hospitalization and intensive care in unadjusted analyses, but associations lost statistical significance with hospitalization and diminished with intensive care after adjusting for clinical measures, including hypertension and

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

blood pressure. However, confidence intervals were wide, include clinically important differences, and conclusions may change as the epidemic evolves. We will continue to update these analyses as more data become available. While this analysis adds information to the evolving pandemic, its limitations must be kept in mind. First, a small proportion of Veterans have been tested and rates of testing vary widely by site. Second, women represented a small number of Veterans in the sample (184 tested, 13 positive). Third, our analysis of outcomes is preliminary as many Covid-19+ patients are still in care. Fourth, while a strength of this analysis is our ability to determine active VA medications, we could only detect NSAID exposure based upon VA pharmacy fill/refill data, individuals are also likely to purchase NSAIDS over the counter. As real-world data become available, more sophisticated and focused pharmacoepidemiological analyses will be required to address concerns regarding potential risk of medications associated with Covid-19. Conclusion Black race was strongly associated with Covid-19+, but not with hospitalization or intensive care. Unadjusted associations between medication exposure, comorbid disease, and hospitalization and intensive care are diminished after adjustment. Risk of hospitalization and

intensive care associated with Covid-19 may be better characterized by vital signs and

measures of physiologic injury than by comorbid conditions or medication history.

Acknowledgements

The views and opinions expressed in this manuscript are those of the authors and do not necessarily represent those of the Department of Veterans Affairs or the United States

Government. The authors wish to recognize Dr. Kendall Bryant as the NIAAA Scientific

Collaborator for the Veterans Birth Cohort. The authors thank Dr. Jennifer Thompson for her feedback regarding helpful data presentation and important characteristics to include to enable statistical modeling of the Covid-19 pandemic.

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372


373


374

375

376

References 1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. 2. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020. 3. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients 4. with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus 5. Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. 6. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions 7. Among Patients with Coronavirus Disease 2019 — United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. doi:http://dx.doi.org/10.15585/mmwr.mm6913e2. Published 31 March 2020. Accessed 31 March 2020.





420 24. Sohrabi C, Alsafi Z, O'Neill N, et al. World Health Organization declares global 421 emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-76. 422 423 Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev 25. 424 Gastroenterol Hepatol. 2016;13(2):88-110. 425 26. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43(2) 426 Suppl 1):S54-62. 427 27. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol. 2001;13(7):777-784. 428 429 430

Figure 1. Distribution of Covid-19 cases in the Veterans Birth Cohort as of March 30, 2020

Caption: (a) Shown is the distribution of 585/1244 (47%) Covid-19 cases in the Veterans Health

Administration captured in the Veterans Birth Cohort as of March 30, 2020 and included in the current study. (b) Shown is the proportion of Covid-19 test results that are positive by the proportion of Covid-19 cases of black race by site of care.

Table 1. Characteristics of patients tested for Covid-19 among all patients aged 54-75 years in the Veterans Health Administration as of March 30, 2020

						COVID	-19 test re	out.	9/ 0:! 10:	
	No. tested	(%)	missing	Positive	(%)	Negative	(%)	p-va lue	% Covid-19+ (95% CI)	
Sample size, n	3789	(100.0)		585	(100.0)	3204	(100.0)	•	15.4 (14.3-16.6	
De mogra phics										
Age, years										
Median (IQR)	65.7 (60.5		0	66.1 (60		65.6 (60.		0.24		
54-59	861	(22.7)		135	(23.1)	726	(22.7)	0.21	15.7 (13.3-18.3	
60-64	906	(23.9)		135	(23.1)	771	(24.1)		14.9 (12.6-17.4	
65-69 70-75	877 1145	(23.1)		120 195	(20.5)	757 950	(23.6) (29.7)		13.7 (11.5-16.1	
70-75 Sex	1145	(30.2)		195	(33.3)	930	(29.7)		17.0 (14.9-19.3	
Female	372	(9.8)	0	27	(4.6)	345	(10.8)	<0.001	7.3 (4.8-10.4)	
Male	34 17	(90.2)		558	(95.4)	2859	(89.2)		16.3 (15.1-17.6	
Race/ethnicity										
White	2135	(56.3)	0	161	(27.5)	1974	(61.6)	<0.001	7.5 (6.5-8.7)	
Black	1126	(29.7)		350	(59.8)	776	(24.2)		31.1 (28.4-33.9	
Latinx	294	(7.8)		48	(8.2)	246	(7.7)		16.3 (12.3-21.1	
Other/unknown Residence type	234	(6.2)		26	(4.4)	208	(6.5)		11.1 (7.4-15.9)	
Rural	718	(18.9)	0	56	(9.6)	662	(20.7)	<0.001	7.8 (6.0-10.0)	
Urban	3071	(81.1)	U	529	(90.4)	2542	(79.3)	\0.001	17.2 (15.9-18.6	
Baseline comorbidity	3071	(01.1)		323	(50.4)	2542	(15.5)		17.2 (15.5 10.0	
Asthma										
No	3506	(92.5)	0	540	(92.3)	2966	(92.6)	0.80	15.4 (14.2-16.6	
Yes	283	(7.5)		45	(7.7)	238	(7.4)		15.9 (11.8-20.7	
Cancer										
No	32 18	(84.9)	0	502	(85.8)	2716	(84.8)	0.57	15.6 (14.4-16.9	
Yes	571	(15.1)		83	(14.2)	488	(15.2)		14.5 (11.8-17.7	
Chronic kidney disease			_							
No	3228	(85.2)	0	474	(81.0)	2754	(86.0)	0.003	14.7 (13.5-16.0	
Yes	561	(14.8)		111	(19.0)	450	(14.0)		19.8 (16.6-23.3	
Chronic obstructive pulmonary disease No	2796	(73.8)	0	495	(84.6)	2301	(71.8)	<0.001	17.7 (16.3-19.2	
Yes	993	(26.2)	Ü	90	(15.4)	903	(28.2)	10.001	9.1 (7.4-11.0)	
Diabetes mellitus	333	(20.2)		50	(25)	505	(20,2)		511 (711 1110)	
No	2358	(62.2)	0	325	(55.6)	2033	(63.5)	<0.001	13.8 (12.4-15.2	
Yes	1431	(37.8)		260	(44.4)	1171	(36.5)		18.2 (16.2-20.3	
Hypertension										
No	1326	(35.0)	0	162	(27.7)	1164	(36.3)	<0.001	12.2 (10.5-14.1	
Yes	2463	(65.0)		423	(72.3)	2040	(63.7)		17.2 (15.7-18.7	
Liver disease										
No	3323	(87.7)	0	525	(89.7)	2798	(87.3)	0.12	15.8 (14.6-17.1	
Yes	466	(12.3)		60	(10.3)	406	(12.7)		12.9 (10-16.3)	
Vascular disease No	2694	(71.1)	0	422	(72.1)	2272	(70.9)	0.59	15.7 (14.3-17.1	
Yes	1095	(28.9)	Ü	163	(27.9)	932	(29.1)	0.33	14.9 (12.8-17.1	
Substance use	2033	(20.5)		200	(27.5)	352	(23.2)		1115 (1210 1711	
Alcohol use disorder										
No	3261	(86.1)	0	537	(91.8)	2724	(85.0)	<0.001	16.5 (15.2-17.8	
Yes	528	(13.9)		48	(8.2)	480	(15.0)		9.1 (6.8-11.9)	
Smoking										
Never	1042	(27.5)	261	216	(36.9)	826	(25.8)	<0.001	20.7 (18.3-23.3	
Former	883	(23.3)		179	(30.6)	704	(22.0)		20.3 (17.7-23.1	
Current	1603	(42.3)		159	(27.2)	1444	(45.1)		9.9 (8.5-11.5)	
Medication history in year prior to test date Any angiotensin converting enzyme inhibitor or angiotensin II receptor blocker										
No	2257	(59.6)	0	330	(56.4)	1927	(60.1)	0.10	14.6 (13.2-16.2	
Yes	1532	(40.4)		255	(43.6)	1277	(39.9)		16.6 (14.8-18.6	
Angiotensin converting enzyme inhibitor										
No	2778	(73.3)	0	416	(71.1)	2362	(73.7)	0.20	15.0 (13.7-16.4	
Yes	1011	(26.7)		169	(28.9)	842	(26.3)		16.7 (14.5-19.2	
Angiotensin II receptor blocker	2226	/OF 4\	0	404	(0.2.0)	2725	(OF 4)	0.20	453/440465	
No V	3226	(85.1)	0	491	(83.9)	2735	(85.4)	0.38	15.2 (14.0-16.5	
Yes Chemotherapy or immunsuppresive drug	563	(14.9)		94	(16.1)	469	(14.6)		16.7 (13.7-20.0	
No	3568	(94.2)	0	556	(95.0)	3012	(94.0)	0.39	15.6 (14.4-16.8	
Yes	221	(5.8)	ū	29	(5.0)	192	(6.0)	5.55	13.1 (9.0-18.3)	
Nonsteroidal anti-inflammatory drug, (-365, -14		, -/			1 -1		1 -1		,	
days)										
No	2634	(69.5)	0	392	(67.0)	2242	(70.0)	0.16	14.9 (13.5-16.3	
Yes	1155	(30.5)		193	(33.0)	962	(30.0)		16.7 (14.6-19.0	
Vital signs at test date										
Body mass index, kg/m ²										
	7.70	(20.6)	393	73	(12.5)	706	(22.0)	< 0.001	9.4 (7.4-11.6)	
<25.0	779		333					.0.001		
<25.0 25.0-29.9 ≥30	1070 1547	(28.2) (40.8)	333	166 291	(28.4) (49.7)	904 1256	(28.2) (39.2)	101001	15.5 (13.4-17.8 18.8 (16.9-20.9	

No	2433	(64.2)	860	443	(75.7)	1990	(62.1)	0.20	18.2 (16.7-19.8)
Yes	496	(13.1)		78	(13.3)	418	(13.0)		15.7 (12.6-19.2)
Pulse ≥90 beats per minute									
No	2033	(53.7)	416	295	(50.4)	1738	(54.2)	<0.001	14.5 (13.0-16.1)
Yes	1340	(35.4)		257	(43.9)	1083	(33.8)		19.2 (17.1-21.4)
Systolic blood pressure, mm Hg									
<90	355	(9.4)	448	63	(10.8)	292	(9.1)	0.11	17.8 (13.9-22.1)
90-140	1565	(41.3)		274	(46.8)	1291	(40.3)		17.5 (15.7-19.5)
≥140	1421	(37.5)		211	(36.1)	1210	(37.8)		14.9 (13.0-16.8)
Temperature, °F		1/			(<i>-</i> /		1/		
≤98.6	2142	(56.5)	405	204	(34.9)	1938	(60.5)	<0.001	9.5 (8.3-10.9)
98.7-100.3	953	(25.2)	403	227	(38.8)	726	(22.7)	10.001	23.8 (21.2-26.7)
≥100.4	289	(7.6)		120	(20.5)	169	(5.3)		41.5 (35.8-47.4)
	203	(7.0)		120	(20.3)	103	(3.3)		41.5 (55.6 47.4)
Laboratory findings at test date									
Alanine aminotransferase, U/L	22.0.4.5.0	2.01	•00	00.0140		000146	0.0001		
Median (IQR)	23.0 (16.0		400	28.0 (19		22.0 (16.		<0.001	
≤40	28 29	(74.7)		406	(69.4)	2423	(75.6)	<0.001	14.4 (13.1-15.7)
>40	560	(14.8)		138	(23.6)	422	(13.2)		24.6 (21.1-28.4)
Albumin, g/dL									
Median (IQR)	3.9 (3.5-	4.2)	383	3.8 (3.		3.9 (3.5		0.78	
≥3.5	2596	(68.5)		4 15	(70.9)	2 18 1	(68.1)	1.00	16.0 (14.6-17.5)
<3.5	8 10	(21.4)		129	(22.1)	681	(21.3)		15.9 (13.5-18.6)
Aspartate aminotransferase, U/L									
Median (IQR)	23.0 (18.0	-32.0)	356	29.0 (21	. 5-43.0)	22.0 (17.	0-30.0)	<0.001	
<u>≤</u> 40	2902	(76.6)		391	(66.8)	2511	(78.4)	<0.001	13.5 (12.3-14.8)
>40	531	(14.0)		157	(26.8)	374	(11.7)		29.6 (25.7-33.7)
Creatinine, mg/dL									
Median (IQR)	1.1 (0.9-	1.3)	186	1.1 (1.)	0-1.5)	1.0 (0.9	9- 1. 3)	<0.001	
≤1.5	3033	(80.0)		435	(74.4)	2598	(81.1)	<0.001	14.3 (13.1-15.6)
>1.5	570	(15.0)		130	(22.2)	440	(13.7)	.0.001	22.8 (19.4-26.5)
eGFR, mL/min	570	(15.0)		150	(22.2)	440	(15.7)		22.0 (15.4 20.5)
Median (IQR)	75.0 (59.0	-9101	168	71.5 (53	0-870\	76.0 (60.	n-a2 nl	<0.001	
≥15	3492	(92.2)	100	541	(92.5)	2951	(92.1)	0.11	15.5 (14.3-16.7)
	129							0.11	
<15	129	(3.4)		27	(4.6)	102	(3.2)		20.9 (14.3-29.0)
FIB-4	4400	/20 Cl	620	420	(22.0)	1200	(40.4)	.0.004	0.2/7.0.40.0\
<1.45	1499	(39.6)	628	139	(23.8)	1360	(42.4)	<0.001	9.3 (7.9-10.9)
1.45-3.25	1266	(33.4)		263	(45.0)	1003	(31.3)		20.8 (18.6-23.1)
>3.25	396	(10.5)		114	(19.5)	282	(8.8)		28.8 (24.4-33.5)
Hemoglobin, g/dL									
Median (IQR)	13.8 (12.2		445	13.9 (12		13.8 (12.		0.09	
≥10	3097	(81.7)		523	(89.4)	2574	(80.3)	<0.001	16.9 (15.6-18.3)
<10	247	(6.5)		17	(2.9)	230	(7.2)		6.9 (4.1-10.8)
Platelet count, K/μL									
Median (IQR)	218 (173-	267)	423	193 (15	4- 230)	223 (17	8- 275)	<0.001	
≥150	2875	(75.9)		416	(71.1)	2459	(76.7)	<0.001	14.5 (13.2-15.8)
<150	491	(13.0)		121	(20.7)	370	(11.5)		24.6 (20.9-28.7)
White blood cell count, K/μL									
Median (IQR)	7.5 (5.7-	10.0)	288	5.9 (4.	7-7.5)	7.8 (6.0	-10.4)	<0.001	
<4	191	(5.0)		72	(12.3)	119	(3.7)	< 0.001	37.7 (30.8-45.0)
4-9.9	2448	(64.6)		432	(73.8)	2016	(62.9)		17.7 (16.2-19.2)
≥10	862	(22.8)		49	(8.4)	813	(25.4)		5.7 (4.2-7.5)
Lymphocyte count, K/μL					, ,				, ,
Median (IQR)	1.4 (1.0-	2 01	628	1.1 (0.	8-1 6)	1.5 (1.0)-2 1\	< 0.001	
≥0.8	2626	(69.3)		363	(62.1)	2263	(70.6)	<0.001	13.8 (12.5-15.2)
<0.8	535	(14.1)		130	(22.2)	405	(12.6)	.0.001	24.3 (20.7-28.2)
	333	(14.1)		130	\ZZ.Z]	403	(12.0)		24.5 (20.7 20.2)
Clinical outcomes									
Hospitalized			_						
No	2277	(60.1)	0	288	(49.2)	1989	(62.1)	<0.001	12.7 (11.3-14.1)
Yes	15 12	(39.9)		297	(50.8)	1215	(37.9)		19.6 (17.7-21.7)
Intensive care unit admission									
No	3381	(89.2)	0	463	(79.1)	2918	(91.1)	<0.001	13.7 (12.6-14.9)
Yes	408	(10.8)		122	(20.9)	286	(8.9)		29.9 (25.5-34.6)
Death during hospitalization									
No	3744	(98.8)	0	5 68	(97.1)	3176	(99.1)	<0.001	15.2 (14.0-16.4)
Yes	45	(1.2)		17	(2.9)	28	(0.9)		37.8 (23.8-53.5)

Yes 45 (1.2) 17 (2.9) 28 (0.9) Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score

^aP-values calculated on non-missing data

Table 2. Crude and adjusted associations with testing positive for Covid-19 as of March 30, 2020

	Positive Covid-19 test (n=585/3789)							
	Univariable OR (95% CI)	Multivariable OR (95% Cl)	Conditional OR ^a (95% CI)					
Model details								
C-statistic	=	0.806	n/a					
Demographics								
Age, per 5-year increase	1.04 (0.97-1.12)	1.05 (0.96-1.15)	1.02 (0.91-1.15)					
Sex, male vs. female	2.49 (1.67-3.73)	3.17 (2.03-4.94)	3.85 (2.20-6.74)					
Race/ethnicity, black vs. other	4.66 (3.88-5.60)	4.68 (3.79-5.78)	2.56 (1.89-3.46)					
Residence type, urban vs. rural	2.46 (1.84-3.28)	1.60 (1.17-2.20)	1.04 (0.64-1.68)					
Baseline comorbidity								
Chronic kidney disease, yes vs. no	1.43 (1.14-1.80)	1.00 (0.76-1.33)	0.92 (0.64-1.31)					
Chronic obstructive pulmonary disease, yes vs. no	0.46 (0.37-0.59)	0.67 (0.50-0.88)	0.77 (0.54-1.09)					
Diabetes mellitus, yes vs. no	1.39 (1.16-1.66)	1.01 (0.80-1.26)	0.89 (0.67-1.19)					
Hypertension, yes vs.no	1.49 (1.23-1.81)	1.23 (0.95-1.60)	1.40 (1.00-1.96)					
Substance use								
Alcohol use disorder, yes vs. no	0.51 (0.37-0.69)	0.58 (0.41-0.83)	0.52 (0.34-0.82)					
Current smoking, yes vs. no	0.43 (0.35-0.52)	0.45 (0.35-0.57)	0.45 (0.34-0.61)					
Medication history in year prior to test date								
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, yes vs. no	1.17 (0.98-1.39)	0.98 (0.78-1.23)	0.93 (0.69-1.24)					
Nonsteroidal anti-inflammatory drug, yes vs. no	1.15 (0.95-1.39)	1.27 (1.02-1.58)	1.16 (0.87-1.54)					
Vital signs								
Systolic blood pressure, <140 vs. ≥140 mm Hg	1.25 (1.03-1.51)	1.44 (1.16-1.78)	1.29 (0.99-1.69)					
Body mass index, per 5 kg/m ² increase	1.15 (1.08-1.23)	1.09 (1.00-1.18)	1.10 (0.99-1.22)					
Oxygen saturation, ≤93% vs >93%	0.88 (0.68-1.15)	1.04 (0.76-1.42)	1.04 (0.67-1.61)					
Pulse, per 5-beats per minute increase	0.99 (0.99-1.00)	0.99 (0.99-1.00)	1.00 (0.99-1.00)					
Temperature, per 1°F increase	1.74 (1.62-1.87)	1.70 (1.58-1.84)	1.69 (1.53-1.88)					

Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval

442

443

444

^aModeling stations with five or more Covid-19 cases and conditioning on station

Table 3a. Associations with hospitalization among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020

		5 years in	-		•		Hos pita li:	ation		
	No. cases	(%)	missing	Yes	(%)	No	(%)	p-va lueª	% hospitalized (95% CI)	
n	585	(100)		297	(100.0)	288	(100.0)		50.8 (46.6-54.9)	
De mogra phics										
Age, years Median (IQR)	66.1 (60.4	I-71N\	0	67.6	(61.7-71.6)	64.5	(59.7-70.5)	0.001		
54-59	135	(23.1)	Ü	58	(19.5)	77	(26.7)	0.001	43.0 (34.5-51.8)	
60-64	135	(23.1)		62	(20.9)	73	(25.3)		45.9 (37.3-54.7)	
65-69	120	(20.5)		62	(20.9)	58	(20.1)		51.7 (42.4-60.9)	
70-75	195	(33.3)		115	(38.7)	80	(27.8)		59.0 (51.7-66.0)	
Sex										
Female	27	(4.6)	0	8	(2.7)	19	(6.6)	0.03	29.6 (13.8-50.2)	
Male Race/ethnicity	558	(95.4)		289	(97.3)	269	(93.4)		51.8 (47.6-56.0)	
White	161	(27.5)	0	79	(26.6)	82	(28.5)	0.32	49.1 (41.1-57.1)	
Black	350	(59.8)	Ü	187	(63.0)	163	(56.6)	0.52	53.4 (48.1-58.8)	
Latinx	48	(8.2)		20	(6.7)	28	(9.7)		41.7 (27.6-56.8)	
Other/unknown	26	(4.4)		11	(3.7)	15	(5.2)		42.3 (23.4-63.1)	
Residence type										
Rural	56	(9.6)	0	27	(9.1)	29	(10.1)	0.78	48.2 (34.7-62.0)	
Urban	529	(90.4)		270	(90.9)	259	(89.9)		51.0 (46.7-55.4)	
Baseline comorbidity										
Asthma										
No	540	(92.3)	0	273	(91.9)	267	(92.7)	0.76	50.6 (46.3-54.9)	
Yes	45	(7.7)		24	(8.1)	21	(7.3)		53.3 (37.9-68.3)	
Cancer	F02	(OF O)	0	252	(04.0)	250	100.01	٥٢٢	FO 2 (4F 7 F4 7)	
No Yes	502 83	(85.8) (14.2)	0	252 45	(84.8) (15.2)	250 38	(86.8) (13.2)	0.55	50.2 (45.7-54.7) 54.2 (42.9-65.2)	
Chronic kidney disease	63	(14.2)		43	(13.2)	30	(13.2)		34.2 (42.3-03.2)	
No	474	(81.0)	0	222	(74.7)	252	(87.5)	<0.001	46.8 (42.3-51.4)	
Yes	111	(19.0)	Ü	75	(25.3)	36	(12.5)	101001	67.6 (58.0-76.2)	
Chronic obstructive pulmonary disease					, ,		, ,		, ,	
No	495	(84.6)	0	236	(79.5)	259	(89.9)	<0.001	47.7 (43.2-52.2)	
Yes	90	(15.4)		61	(20.5)	29	(10.1)		67.8 (57.1-77.3)	
Diabetes mellitus										
No	325	(55.6)	0	141	(47.5)	184	(63.9)	<0.001	43.4 (37.9-49.0)	
Yes	260	(44.4)		156	(52.5)	104	(36.1)		60.0 (53.8-66.0)	
Hypertension	162	(27.7)	0	F0	(10.0)	102	/ar e)	40.001	26.4.(20.0.44.2)	
No Yes	162 423	(27.7) (72.3)	0	59 238	(19.9) (80.1)	103 185	(35.8) (64.2)	<0.001	36.4 (29.0-44.3)	
Liver disease	423	(72.5)		230	(00.1)	103	(04.2)		56.3 (51.4-61.1)	
No	525	(89.7)	0	260	(87.5)	265	(92.0)	0.08	49.5 (45.2-53.9)	
Yes	60	(10.3)	Ü	37	(12.5)	23	(8.0)	0.00	61.7 (48.2-73.9)	
Vascular disease		,/			1/		1/		(, ,	
No	422	(72.1)	0	184	(62.0)	238	(82.6)	<0.001	43.6 (38.8-48.5)	
Yes	163	(27.9)		113	(38.0)	50	(17.4)		69.3 (61.6-76.3)	
Substance use										
Alcohol use disorder										
No	537	(91.8)	0	269	(90.6)	268	(93.1)	0.29	50.1 (45.8-54.4)	
Yes	48	(8.2)		28	(9.4)	20	(6.9)		58.3 (43.2-72.4)	
Smoking	0.4.0	125.01		40.0	(05.7)	440	(20.0)			
Never	216	(36.9)	31	106	(35.7)	110	(38.2)	0.30	49.1 (42.2-55.9)	
Former Current	179 159	(30.6) (27.2)		89 90	(30.0) (30.3)	90 69	(31.3) (24.0)		49.7 (42.2-57.3) 56.6 (48.5-64.4)	
Medication history in year prior to test date	133	(27.2)		30	(30.3)	03	(24.0)		30.0 (48.3-04.4)	
Any angiotensin converting enzyme inhibitor or angiotensin Il receptor blocker										
No	330	(56.4)	0	150	(50.5)	180	(62.5)	0.004	45.5 (40.0-51.0)	
Yes	255	(43.6)		147	(49.5)	108	(37.5)		57.7 (51.3-63.8)	
Angiotensin converting enzyme inhibitor										
No	416	(71.1)	0	194	(65.3)	222	(77.1)	0.002	46.6 (41.8-51.6)	
Yes	169	(28.9)		103	(34.7)	66	(22.9)		61.0 (53.2-68.4)	
Angiotensin II receptor blocker			_							
No	491	(83.9)	0	248	(83.5)	243	(84.4)	0.82	50.5 (46.0-55.0)	
Yes	94	(16.1)		49	(16.5)	45	(15.6)		52.1 (41.6-62.5)	
Chemotherapy or immunsuppresive drug No	556	(95.0)	0	279	(93.9)	277	(96.2)	0.25	50.2 (45.9-54.4)	
Yes	29	(5.0)	U	18	(6.1)	11	(3.8)	0.23	62.1 (42.3-79.3)	
Nonsteroidal anti-inflammatory drug, (-365, -14 days)	25	(3.0)		10	(0.1)		(5.0)		02.1 (42.5 75.5)	
No	392	(67.0)	0	207	(69.7)	185	(64.2)	0.19	52.8 (47.7-57.8)	
Yes	193	(33.0)		90	(30.3)	103	(35.8)		46.6 (39.4-53.9)	
Vital signs at test date		. ,							, ,	
Body mass index, kg/m ²										
<25.0	73	(12.5)	55	45	(15.2)	28	(9.7)	0.25	61.6 (49.5-72.8)	
25.0-29.9	166	(28.4)		85	(28.6)	81	(28.1)		51.2 (43.3-59.0)	
≥30	291	(49.7)		149	(50.2)	142	(49.3)		51.2 (45.3-57.1)	
Hypoxia (oxygen saturation ≤9 3%)										
No	443	(75.7)	64	226	(76.1)	217	(75.3)	<0.001	51.0 (46.3-55.8)	

V	70	/42.21			/40 F)	20	16.01		74.4.(63.3.03.6)
Yes	78	(13.3)		58	(19.5)	20	(6.9)		74.4 (63.2-83.6)
Pulse ≥90 beats per minute	205	/FO 4\	2.2	450	/EO E\	445	/EQ 21	0.20	FO O /4F O F C 7\
No Yes	295	(50.4)	33	150	(50.5)	145 112	(50.3)	0.20	50.9 (45.0-56.7)
	257	(43.9)		145	(48.8)	112	(38.9)		56.4 (50.1-62.6)
Systolic blood pressure, mm Hg <90	63	(10.0)	37	4.2	(14.5)	20	(6.9)	0.04	C0 2 /FF 2 70 4)
90-140	274	(10.8)	3/	43	(14.5)	20		0.04	68.3 (55.3-79.4)
		(46.8)		145	(48.8)	129	(44.8)		52.9 (46.8-59.0)
≥140 T	211	(36.1)		106	(35.7)	105	(36.5)		50.2 (43.3-57.2)
Temperature, °F ≤98.6	204	(24.0)	34	88	/20.61	116	(40.3)	0.002	42 1 /26 2 EO 2\
98.7-100.3	204	(34.9) (38.8)	34	134	(29.6) (45.1)	93	(32.3)	0.002	43.1 (36.2-50.2) 59.0 (52.3-65.5)
98.7-100.5 ≥100.4	120	(20.5)		70	(23.6)	50	(17.4)		58.3 (49.0-67.3)
	120	(20.5)		70	(23.0)	30	(17.4)		36.3 (43.0-07.3)
Laboratory findings at test date									
Alanine aminotransferase, U/L Median (IQR)	20.0/10.0	110	41	20.0/	20.0-42.0)	2001	18.0-37.0)	0.01	
Median (TQR) ≤40	28.0 (19.0 406	(69.4)	41	30.0 (205	(69.0)	20.0 ((69.8)	0.01	EO E /4E E EE E\
>40				203 87				0.01	50.5 (45.5-55.5)
	138	(23.6)		87	(29.3)	51	(17.7)		63.0 (54.4-71.1)
Albumin, g/dL Median (IQR)	3.8 (3.5	4.2\	41	2.7	(2.2.4.0)	4.1	(3.7-4.3)	<0.001	
≥3.5	415		41	191	(3.3-4.0) (64.3)	224	(77.8)	<0.001	46.0 (41.2-51.0)
<3.5	129	(70.9)		103		26		<0.001	79.8 (71.9-86.4)
Aspartate a min otransferase, U/L	129	(22.1)		103	(34.7)	20	(9.0)		79.6 (71.9-66.4)
Median (IQR)	29.0 (2 1.5	2-43 O)	37	35.5.1	25.0-54.0)	25.0.7	20.0-33.0)	< 0.001	
≤40	391	(66.8)	31	173	(58.2)	218	(75.7)	<0.001	44.3 (39.3-49.3)
>40	157	(26.8)		121	(40.7)	36	(12.5)	10.001	77.1 (69.7-83.4)
Creatinine, mg/dL	137	(20.0)		121	(40.7)	30	(12.3)		77.1 (05.7-65.4)
Median (IQR)	1.1 (1.0	-15)	20	1.3	(1.0-1.8)	1.1	(0.9-1.3)	< 0.001	
≤1.5	435	(74.4)	20	200	(67.3)	235	(81.6)	<0.001	46.0 (41.2-50.8)
>1.5	130	(22.2)		97	(32.7)	33	(11.5)	VO.001	74.6 (66.2-81.8)
eGFR, mL/min	130	(22.2)		37	(32.7)	33	(11.5)		74.0 (00.2 01.0)
Median (IQR)	71.5 (53.0	1-8701	17	63.0 /	42.0-82.0)	75 O /	64.0-93.0)	< 0.001	
≥15	541	(92.5)		277	(93.3)	264	(91.7)	0.03	51.2 (46.9-55.5)
<15	27	(4.6)		20	(6.7)	7	(2.4)	0.00	74.1 (53.7-88.9)
FIB-4		(0)		2.0	(0.7)	•	(=,		7 112 (3317 3313)
<1.45	139	(23.8)	69	36	(12.1)	103	(35.8)	<0.001	25.9 (18.9-34.0)
1.45-3.25	263	(45.0)		153	(51.5)	110	(38.2)		58.2 (52.0-64.2)
>3.25	114	(19.5)		94	(31.6)	20	(6.9)		82.5 (74.2-88.9)
Hemoglobin, g/dL					, ,		, ,		
Median (IQR)	13.9 (12.6	5-14.9)	45	13.6 (12.0-14.7)	14.2 (13.2-15.1)	<0.001	
≥10	523	(89.4)		273	(91.9)	250	(86.8)	0.02	52.2 (47.8-56.6)
<10	17	(2.9)		14	(4.7)	3	(1.0)		82.4 (56.6-96.2)
Platelet count, K/μL									
Median (IQR)	193 (154	- 230)	48	175 (143- 216)	208 (173- 252)	<0.001	
≥150	416	(71.1)		200	(67.3)	216	(75.0)	< 0.001	48.1 (43.2-53.0)
<150	121	(20.7)		88	(29.6)	33	(11.5)		72.7 (63.9-80.4)
White blood cell count, K/µL									
Median (IQR)	5.9 (4.7	-7.5)	32	5.9	(4.6-7.7)	5.9	(4.7-7.3)	0.54	
<4	72	(12.3)		42	(14.1)	30	(10.4)	0.005	58.3 (46.1-69.9)
4-9.9	432	(73.8)		217	(73.1)	215	(74.7)		50.2 (45.4-55.1)
≥10	49	(8.4)		36	(12.1)	13	(4.5)		73.5 (58.9-85.1)
Lymphocyte count, K/μL									
Median (IQR)	1.1 (0.8	-1.6)	92	0.9	(0.6-1.3)	1.4	(1.0-1.9)	< 0.001	
≥0.8	363	(62.1)		179	(60.3)	184	(63.9)	<0.001	49.3 (44.1-54.6)
<0.8	130	(22.2)		105	(35.4)	25	(8.7)		80.8 (72.9-87.2)
VACS Index score ^b , median (IQR)	72.4 (63.6	5-8 2.5)	51	78.7 (71.1-87.3)	66.2 (60.0-73.2)	<0.001	
ALL 1-1 C 1140 1 1 2 2040 IOD 1 -									A to Color to the color of

Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

⁸P-values calculated on non-missing data

^bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index

Table 3b. Associations with intensive care among Covid-19 cases aged 54-75 years in the Veterans Health Administration as of March 30, 2020

			=				Inte ns ive	Cale	% admitted (95%	
	No. cases	(%)	missing	Yes	(%)	No	(%)	p-va lue	% admitted (95% CI)	
n	585	(100)	IIIIssiiig	122	(100.0)	463	(100.0)	p-value	20.9 (17.6-24.4)	
De mogra phics					, ,		, ,		, ,	
Age, years										
Median (IQR)	66.1 (60.4	-71.0)	0	69.9	64.4-71.7)	64.7 (59.8-70.8)	< 0.001		
54-59	135	(23.1)		11	(9.0)	124	(26.8)	<0.001	8.2 (4.1-14.1)	
60-64	135	(23.1)		24	(19.7)	111	(24.0)		17.8 (11.7-25.3)	
65-69	120	(20.5)		28	(23.0)	92	(19.9)		23.3 (16.1-31.9)	
70-75	195	(33.3)		59	(48.4)	136	(29.4)		30.3 (23.9-37.2)	
Sex	27	14.61	0	2	/o. =\	2.4	/E 2\	0.22	44.4/2.4.20.21	
Female Male	27 558	(4.6)	0	3 119	(2.5)	420	(5.2)	0.33	11.1 (2.4-29.2)	
Race/ethnicity	558	(95.4)		119	(97.5)	439	(94.8)		21.3 (18.0-25.0)	
White	161	(27.5)	0	37	(30.3)	124	(26.8)	0.89	23.0 (16.7-30.3)	
Black	350	(59.8)	U	71	(58.2)	279	(60.3)	0.05	20.3 (16.2-24.9)	
Latinx	48	(8.2)		9	(7.4)	39	(8.4)		18.8 (9.0-32.6)	
Other/unknown	26	(4.4)		5	(4.1)	21	(4.5)		19.2 (6.6-39.4)	
Residence type		1/		-	1 =/		1=/		()	
Rural	56	(9.6)	0	9	(7.4)	47	(10.2)	0.49	16.1 (7.6-28.3)	
Urban	529	(90.4)	-	113	(92.6)	416	(89.8)		21.4 (17.9-25.1)	
Baseline comorbidity									, ,	
Asthma										
No	540	(92.3)	0	111	(91.0)	429	(92.7)	0.57	20.6 (17.2-24.2)	
Yes	45	(7.7)		11	(9.0)	34	(7.3)		24.4 (12.9-39.5)	
Cancer									, ,	
No	502	(85.8)	0	104	(85.2)	398	(86.0)	0.88	20.7 (17.3-24.5)	
Yes	83	(14.2)		18	(14.8)	65	(14.0)		21.7 (13.4-32.1)	
Chronic kidney disease										
No	474	(81.0)	0	90	(73.8)	384	(82.9)	0.03	19.0 (15.6-22.8)	
Yes	111	(19.0)		32	(26.2)	79	(17.1)		28.8 (20.6-38.2)	
Chronic obstructive pulmonary disease										
No	495	(84.6)	0	94	(77.0)	401	(86.6)	0.02	19.0 (15.6-22.7)	
Yes	90	(15.4)		28	(23.0)	62	(13.4)		31.1 (21.8-41.7)	
Diabetes mellitus			_							
No 	325	(55.6)	0	49	(40.2)	276	(59.6)	<0.001	15.1 (11.4-19.4)	
Yes	260	(44.4)		73	(59.8)	187	(40.4)		28.1 (22.7-34.0)	
Hypertension	163	(27.7)	0	17	(12.0)	145	(24.2)	10.001	10 5 (6 2 16 2)	
No Yes	162 423	(27.7) (72.3)	0	17 105	(13.9)	145 318	(31.3) (68.7)	<0.001	10.5 (6.2-16.3)	
Liver disease	423	(72.5)		103	(86.1)	210	(00.7)		24.8 (20.8-29.2)	
No	525	(89.7)	0	107	(87.7)	418	(90.3)	0.40	20.4 (17.0-24.1)	
Yes	60	(10.3)	U	15	(12.3)	415	(9.7)	0.40	25.0 (14.7-37.9)	
Vascular disease	00	(10.5)		13	(12.5)	43	(3.7)		25.0 (14.7 57.5)	
No	422	(72.1)	0	74	(60.7)	348	(75.2)	0.002	17.5 (14.0-21.5)	
Yes	163	(27.9)	Ü	48	(39.3)	115	(24.8)	0.002	29.5 (22.6-37.1)	
Substance use		,/			1/		1/		(
Alcohol use disorder										
No	537	(91.8)	0	115	(94.3)	422	(91.1)	0.35	21.4 (18.0-25.1)	
Yes	48	(8.2)		7	(5.7)	41	(8.9)		14.6 (6.1-27.8)	
Smoking									, ,	
Never	216	(36.9)	31	43	(35.2)	173	(37.4)	0.60	19.9 (14.8-25.9)	
Former	179	(30.6)		36	(29.5)	143	(30.9)		20.1 (14.5-26.7)	
Current	159	(27.2)		38	(23.9)	121	(26.1)		23.9 (17.5-31.3)	
Medication history in year prior to test date Any angiotensin converting enzyme inhibitor or angiotensin Il receptor blocker										
No	330	(56.4)	0	53	(43.4)	277	(59.8)	0.001	16.1 (12.3-20.5)	
Yes	255	(43.6)	U	69	(56.6)	186	(40.2)	0.001	27.1 (21.7-33.0)	
Angiotensin converting enzyme inhibitor	233	(40.0)		03	(30.0)	100	140.21		21.1 (21.7-33.0)	
No	416	(71.1)	0	72	(59.0)	344	(74.3)	0.002	17.3 (13.8-21.3)	
Yes	169	(28.9)	J	50	(41.0)	119	(25.7)	0.002	29.6 (22.8-37.1)	
	100	(20.5)		30	(12.0)		(2317)		2310 (2210 3712)	
		(83.9)	0	99	(81.1)	392	(84.7)	0.34	20.2 (16.7-24.0)	
Angiotensin II receptor blocker	491			23	(18.9)	71	(15.3)		24.5 (16.2-34.4)	
Angiotensin II receptor blocker No	491 94								, ,	
Angiotensin II receptor blocker No Yes	491 94	(16.1)		23						
Angiotensin II receptor blocker No Yes			0	115	(94.3)	441	(95.2)	0.64	20.7 (17.4-24.3)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug	94	(16.1)	0		(94.3) (5.7)	441 22	(95.2) (4.8)	0.64	20.7 (17.4-24.3) 24.1 (10.3-43.5)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes	94 556	(16.1) (95.0)	0	115				0.64		
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes	94 556	(16.1) (95.0)	0	115				0.64		
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days)	94 556 29	(16.1) (95.0) (5.0)		115 7	(5.7)	22	(4.8)		24.1 (10.3-43.5)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes	94 556 29 392	(16.1) (95.0) (5.0) (67.0)		115 7 90	(5.7) (73.8)	22 302	(4.8) (65.2)		24.1 (10.3-43.5) 23.0 (18.9-27.5)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes Vital signs at test date	94 556 29 392	(16.1) (95.0) (5.0) (67.0)		115 7 90	(5.7) (73.8)	22 302	(4.8) (65.2)		24.1 (10.3-43.5) 23.0 (18.9-27.5)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes Vital signs at test date	94 556 29 392	(16.1) (95.0) (5.0) (67.0)		115 7 90	(5.7) (73.8)	22 302	(4.8) (65.2)		24.1 (10.3-43.5) 23.0 (18.9-27.5)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes Vital signs at test date Body mass index, kg/m²	94 556 29 392 193	(16.1) (95.0) (5.0) (67.0) (33.0)	0	115 7 90 32	(5.7) (73.8) (26.2)	302 161	(4.8) (65.2) (34.8)	0.08	24.1 (10.3-43.5) 23.0 (18.9-27.5) 16.6 (11.6-22.6)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes Vital signs at test date Body mass index, kg/m² <25.0	94 556 29 392 193	(16.1) (95.0) (5.0) (67.0) (33.0)	0	115 7 90 32	(5.7) (73.8) (26.2) (15.6)	22 302 161 54	(4.8) (65.2) (34.8)	0.08	24.1 (10.3-43.5) 23.0 (18.9-27.5) 16.6 (11.6-22.6) 26.0 (16.5-37.6)	
Angiotensin II receptor blocker No Yes Chemotherapy or immunsuppresive drug No Yes Nonsteroidal anti-inflammatory drug, (-365, -14 days) No Yes Vital signs at test date Body mass index, kg/m² <25.0 25.0-29.9	94 556 29 392 193 73 166	(16.1) (95.0) (5.0) (67.0) (33.0) (12.5) (28.4)	0	115 7 90 32 19 28	(5.7) (73.8) (26.2) (15.6) (23.0)	22 302 161 54 138	(4.8) (65.2) (34.8) (11.7) (29.8)	0.08	24.1 (10.3-43.5) 23.0 (18.9-27.5) 16.6 (11.6-22.6) 26.0 (16.5-37.6) 16.9 (11.5-23.5)	

Yes	78	(13.3)		30	(24.6)	48	(10.4)		38.5 (27.7-50.2)
Pulse ≥90 beats per minute	205	/FO 4\	2.2	F.2	(42.4)	242	/F2 2\	0.00	40.0 /42.0 22.0\
No	295	(50.4)	33	53	(43.4)	242	(52.3)	0.02	18.0 (13.8-22.8)
Yes	257	(43.9)		68	(55.7)	189	(40.8)		26.5 (21.2-32.3)
Systolic blood pressure, mm Hg		140.01			140.01		10.01	0.57	07.0 (46.6.00.7)
<90	63	(10.8)	37	17	(13.9)	46	(9.9)	0.57	27.0 (16.6-39.7)
90-140	274	(46.8)		60	(49.2)	214	(46.2)		21.9 (17.2-27.3)
≥140	211	(36.1)		44	(36.1)	167	(36.1)		20.9 (15.6-27.0)
Temperature, °F									
≤98.6	204	(34.9)	34	28	(23.0)	176	(38.0)	0.002	13.7 (9.3-19.2)
98.7-100.3	227	(38.8)		56	(45.9)	171	(36.9)		24.7 (19.2-30.8)
≥100.4	120	(20.5)		34	(27.9)	86	(18.6)		28.3 (20.5-37.3)
Laboratory findings at test date									
Alanine aminotransferase, U/L									
Median (IQR)	28.0 (19.0		41		21.0-47.0)		19.0-38.0)	0.02	
≤40	406	(69.4)		78	(63.9)	328	(70.8)	0.004	19.2 (15.5-23.4)
>40	138	(23.6)		43	(35.2)	95	(20.5)		31.2 (23.6-39.6)
Albumin, g/dL									
Median (IQR)	3.8 (3.5-		41		(3.2-3.9)		(3.6-4.2)	<0.001	
≥3.5	415	(70.9)		68	(55.7)	347	(74.9)	<0.001	16.4 (13.0-20.3)
<3.5	129	(22.1)		54	(44.3)	75	(16.2)		41.9 (33.2-50.9)
Aspartate amin otransferase, U/L									
Median (IQR)	29.0 (2 1.5		37		27.0-68.0)		21.0-39.0)	<0.001	
≤ 40	391	(66.8)		59	(48.4)	332	(71.7)	<0.001	15.1 (11.7-19.0)
>40	157	(26.8)		63	(51.6)	94	(20.3)		40.1 (32.4-48.2)
Creatinine, mg/dL									
Median (IQR)	1.1 (1.0-		20		(1.1-2.0)		(0.9-1.4)	<0.001	
≤1.5	435	(74.4)		72	(59.0)	363	(78.4)	<0.001	16.6 (13.2-20.4)
>1.5	130	(22.2)		50	(41.0)	80	(17.3)		38.5 (30.1-47.4)
eGFR, mL/min									
Median (IQR)	71.5 (53.0	-8 7.0)	17		37.0-76.0)	74.0 (58.0-90.0)	<0.001	
≥15	541	(92.5)		110	(90.2)	431	(93.1)	0.006	20.3 (17.0-24.0)
<15	27	(4.6)		12	(9.8)	15	(3.2)		44.4 (25.5-64.7)
FIB-4									
<1.45	139	(23.8)	69	6	(4.9)	133	(28.7)	<0.001	4.3 (1.6-9.2)
1.45-3.25	263	(45.0)		66	(54.1)	197	(42.5)		25.1 (20.0-30.8)
>3.25	114	(19.5)		44	(36.1)	70	(15.1)		38.6 (29.6-48.2)
Hemoglobin, g/dL									
Median (IQR)	13.9 (12.6	-14.9)	45	13.6 (11.9-14.7)	14.0 (12.8-15.0)	0.02	
≥10	523	(89.4)		109	(89.3)	414	(89.4)	0.02	20.8 (17.4-24.6)
<10	17	(2.9)		8	(6.6)	9	(1.9)		47.1 (23.0-72.2)
Platelet count, K/μL									
Median (IQR)	193 (154	- 230)	48	175 (144- 228)	195 (157- 231)	0.05	
≥150	416	(71.1)		82	(19.7)	334	(72.1)	0.03	19.7 (16.0-23.9)
<150	121	(20.7)		35	(28.9)	86	(18.6)		28.9 (21.1-37.9)
White blood cell count, K/μL									
Median (IQR)	5.9 (4.7-	7.5)	32	6.2	(5.2-8.9)	5.7	(4.6-7.2)	<0.001	
<4	72	(12.3)		12	(16.7)	60	(13.0)	0.002	16.7 (8.9-27.3)
4-9.9	432	(73.8)		89	(20.6)	343	(74.1)		20.6 (16.9-24.7)
≥10	49	(8.4)		21	(42.9)	28	(6.0)		42.9 (28.8-57.8)
Lymphocyte count, K/μL									
Median (IQR)	1.1 (0.8-	1.6)	92	0.8	(0.6-1.1)	1.2	(0.8-1.8)	<0.001	
≥0.8	363	(62.1)		71	(19.6)	292	(63.1)	<0.001	19.6 (15.6-24.0)
<0.8	130	(22.2)		48	(36.9)	82	(17.7)		36.9 (28.6-45.8)
VACS Index score ^b , median (IQR)	72.4 (63.6	-8 2.5)	51	82.0 (74.0-91.1)	69.4 (61.1-79.1)	<0.001	
ALL 141 C 1140 11 11 2040 IOD 14									A 1 C b acc d

Abbreviations: Covid-19, coronavirus disease 2019; IQR, interquartile range; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

⁸P-values calculated on non-missing data

^bThe VACS Index score is a validated measure of physiologic injury and combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index


Table 4. Crude and adjusted associations with hospitalization and intensive care among Covid-19 cases as of March 30, 2020

	Hos	pitalization (n=297/	585)	Intensive care (n=122/585)					
	Univariable OR (95% Cl)	Multivariable OR (95% CI)	Multivariable OR (95% CI)	Univariable OR (95% CI)	Multivariable OR (95% CI)	Multivariable OR (95% CI)			
Model details									
C-statistic	-	0.859	0.834	=	0.876	0.835			
Demographics									
Age, per 5-year increase	1.26 (1.10-1.44)	0.87 (0.71-1.05)	0.64 (0.51-0.80)	1.55 (1.30-1.86)	1.31 (1.03-1.66)	0.98 (0.76-1.26)			
Race/ethnicity, black vs. other	1.30 (0.94-1.82)	0.96 (0.61-1.53)	1.14 (0.74-1.74)	0.92 (0.61-1.38)	0.94 (0.55-1.63)	0.98 (0.60-1.61)			
Baseline comorbidity									
Chronic kidney disease, yes vs. no	2.36 (1.53-3.66)	0.80 (0.41-1.56)	0.84 (0.47-1.49)	1.73 (1.08-2.77)	0.50 (0.24-1.06)	0.65 (0.35-1.21)			
Chronic obstructive pulmonary disease, yes vs. no	2.31 (1.43-3.72)	1.77 (0.92-3.41)	1.15 (0.62-2.12)	1.93 (1.17-3.18)	1.81 (0.92-3.58)	1.47 (0.79-2.73)			
Diabetes mellitus, yes vs. no	1.96 (1.41-2.73)	1.59 (1.00-2.53)	1.36 (0.89-2.09)	2.20 (1.46-3.30)	1.69 (0.96-2.98)	1.41 (0.85-2.35)			
Hypertension, yes vs.no	2.25 (1.55-3.26)	1.39 (0.78-2.46)	1.50 (0.88-2.54)	2.81 (1.63-4.88)	1.51 (0.70-3.28)	1.89 (0.93-3.87)			
Vascular disease, yes vs. no	2.92 (1.99-4.29)	1.58 (0.93-2.69)	1.58 (0.96-2.60)	1.96 (1.29-2.99)	0.73 (0.40-1.33)	0.77 (0.44-1.34)			
Medication history in year prior to test date									
Angiotensin converting enzyme inhibitor or angiotensin receptor blocker, yes vs. no	1.63 (1.17-2.27)	1.15 (0.71-1.87)	1.24 (0.79-1.95)	1.94 (1.30-2.90)	1.66 (0.94-2.93)	1.69 (1.01-2.84)			
Nonsteroidal anti-inflammatory drug, yes vs. no	0.78 (0.55-1.10)	1.18 (0.74-1.89)	1.09 (0.71-1.67)	0.67 (0.43-1.04)	1.16 (0.65-2.06)	0.98 (0.57-1.67)			
Vital signs									
Systolic blood pressure, per 5 mm Hg decrease	1.10 (1.03-1.17)	1.08 (1.00-1.18)	1.09 (1.00-1.17)	1.05 (0.98-1.13)	1.00 (0.92-1.10)	1.00 (0.91-1.09)			
Oxygen saturation, per 1% decrease	1.14 (1.06-1.23)	1.04 (0.95-1.14)	1.12 (1.02-1.22)	1.16 (1.09-1.24)	1.05 (0.97-1.14)	1.13 (1.05-1.21)			
Pulse, per 5-beats per minute increase	0.97 (0.95-0.99)	0.97 (0.95-099)	0.97 (0.95-0.99)	0.99 (0.97-1.00)	1.00 (0.97-1.02)	0.99 (0.97-1.01)			
Temperature, per 1°F increase	1.20 (1.07-1.36)	1.15 (0.98-1.34)	1.24 (1.08-1.44)	1.28 (1.12-1.47)	1.32 (1.10-1.58)	1.37 (1.16-1.61)			
Laboratory findings									
Albumin, per 1 g/dL decrease	10.43 (5.70-19.08)	3.75 (1.91-7.35)	-	6.17 (3.62-10.52)	3.34 (1.70-6.54)	-			
eGFR, per 10 mL/min decrease	1.29 (1.19-1.40)	1.18 (1.05-1.32)	-	1.31 (1.21-1.43)	1.29 (1.15-1.46)	-			
FIB-4									
<1.45	ref	ref	=	ref	ref	=			
1.45-3.25	3.92 (2.53-6.08)	2.96 (1.69-5.17)	=	6.31 (2.74-14.50)	4.59 (1.72-12.22)	=			
>3.25	12.37 (6.73-22.72)	8.73 (4.11-18.56)	Ē	12.43 (5.24-29.50)	8.40 (2.90-24.28)	Ξ			
Hemoglobin, per 1 g/dL decrease	1.55 (1.32-1.83)	1.16 (0.93-1.43)	-	1.33 (1.14, 1.54)	1.00 (0.81-1.23)	-			
White blood cell count, per 1 K/μL increase	1.05 (0.96-1.15)	1.24 (1.08-1.43)	-	1.22 (1.10-1.36)	1.49 (1.27-1.73)	-			
Lymphocyte count, per 1 K/μL decrease	2.68 (2.00-3.60)	2.38 (1.68-3.39)	-	2.76 (1.87-4.09)	2.65 (1.68-4.18)	-			
VACS Index score ^a , per 5-point increase	1.48 (1.36-1.61)	-	1.62 (1.43-1.84)	1.45 (1.33-1.58)	-	1.47 (1.31-1.65)			

Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; Cl, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study

^aThe VACS Index score is a validated measure of physiologic injury combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index

Figure 1. Distribution of Covid-19 cases in the Veterans Birth Cohort as of March 30, 2020



(a) Shown is the distribution of 585/1244 (47%) Covid-19 cases in the Veterans Health Administration captured in the Veterans Birth Cohort as of March 30, 2020 and included in the current study. (b) Shown is the proportion of Covid-19 test results that are positive by the proportion of Covid-19 cases of black race by site of care.